CORNING, N.Y. — Corning Incorporated (NYSE: GLW) will showcase its latest drug discovery solutions in exhibit 1231 at the Society for Laboratory Automation & Screening (SLAS) 2016 Conference, January 23 – 27 in San Diego, California.
Corning will feature innovations and laboratory solutions including:
- The Corning® spheroid microplate
- Corning glass-bottom and cyclic olefin copolymer (COC) film-bottom microplates for high-content screening
- The new Corning® HepatoCells
- The recently launched Axygen® automation-compatible PCR microplate
“Corning products help our customers optimize their assays and streamline high throughput screening,” said Richard Eglen, Ph.D., vice president and general manager, Corning Life Sciences. “Corning is leveraging its capabilities in precision forming and its life sciences industry experience to help researchers focus on the discovery and development of new ways to treat disease. And, we’re committed to developing innovative solutions that accelerate discovery.”
The 96-well and 384-well spheroid microplates feature a novel and proprietary design ideal for generating and analyzing 3D multicellular spheroids in a single, automation-friendly microplate. This design features Corning’s ultra-low attachment surface and a black opaque microplate body that shields each optically clear well from crosstalk. Together, these features enable users to reproducibly form a single, unique spheroid in each well and successfully perform assays in the same plate.
“3D cell culture is an important emerging application area where broad adoption in screening has been limited by cost and complexity of the assays,” said Keith R. Olson, Ph.D., Corning Cell Culture business director. “Corning spheroid microplates allow our customers to reduce the number of steps in generating 3D multicellular spheroids and operate in a screening environment more effectively.”
Corning now provides a full portfolio of glass-bottom and COC film-bottom microplates that are ideal for high-content screening and imaging applications. These high-optical quality microplates provide industry-leading flatness that reduces autofocus time, increases throughput, and improves high-content screening assay performance.
The new Axygen® automation-compatible PCR microplate offers a unique design to prevent plate warping and minimize evaporation during thermal cycling. A rigid frame with a small split sustains heat transfer during cycling without distorting its shape. The plate is the latest addition to a large portfolio of automation consumables including the extensive range of Axygen automation tips for liquid handling.
New Corning® HepatoCells offer a renewable alternative to primary hepatocytes that is consistent and convenient. This exciting new product delivers robust induction response for major Cytochrome P450 (CYP) enzymes combined with the reliability and reproducibility benefits of a homogeneous cell line.
Corning will also feature additional solutions for lab automation, drug screening, and cancer research at SLAS.
During the SLAS2016 meeting, Eglen will be appointed president of SLAS after serving the past two years as an officer on the board of directors. Eglen was elected to the board of directors in 2014 in recognition of his achievements and leadership in the life science industry and the SLAS scientific community.
Eglen will be available for interviews to discuss Corning’s latest innovations and participate on a panel focused on 3D cell culture from 8 to 9:15 a.m., Tuesday, January 26, Room 14B, in the San Diego Convention Center.
Corning Life Sciences brings new and innovative laboratory technologies to researchers worldwide and helps customers succeed by providing innovative, high-quality products and services in the areas of polymer science, biochemistry and molecular biology, glass melting and forming, surface modification, and characterization science.
To learn more about Corning Life Sciences products, please contact a customer service representative at 1-800-492-1110, toll free in the United States; (+1) 1-978-442-2200 internationally; or visit www.corning.com/lifesciences.
Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.
Digital Media Disclosure
In accordance with guidance provided by the SEC regarding the use of company websites and social media channels to disclose material information, Corning Incorporated (“Corning”) wishes to notify investors, media, and other interested parties that it intends to use its website (http://www.corning.com/worldwide/en/about-us/news-events.html) to publish important information about the company, including information that may be deemed material to investors. The list of websites and social media channels that the company uses may be updated on Corning’s media and website from time to time. Corning encourages investors, media, and other interested parties to review the information Corning may publish through its website and social media channels as described above, in addition to the company’s SEC filings, press releases, conference calls, and webcasts.
About Corning Incorporated
Corning (www.corning.com) is one of the world’s leading innovators in materials science. For more than 160 years, Corning has applied its unparalleled expertise in specialty glass, ceramics, and optical physics to develop products that have created new industries and transformed people’s lives. Corning succeeds through sustained investment in R&D, a unique combination of material and process innovation, and close collaboration with customers to solve tough technology challenges. Corning’s businesses and markets are constantly evolving. Today, Corning’s products enable diverse industries such as consumer electronics, telecommunications, transportation, and life sciences. They include damage-resistant cover glass for smartphones and tablets; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for high-speed communications networks; trusted products that accelerate drug discovery and manufacturing; and emissions-control products for cars, trucks, and off-road vehicles.